Article

On optimal temozolomide scheduling for slowly growing gliomas

2022-03-11

Abstract excerpt

<h4>Background</h4> Temozolomide (TMZ) is an oral alkylating agent active against gliomas with a favorable toxicity profile. It is part of the standard of care in the management of glioblastoma, and is commonly used in low-grade gliomas. In-silico mathematical models can potentially be used to personalize treatments and to accelerate the discovery of optimal drug delivery schemes. <h4>Methods</h4> Agent-based...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0e9d8f68-3a80-5894-bd98-da1ff34c2165
DOI: 10.1101/2022.03.10.482967

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

On optimal temozolomide scheduling for slowly growing gliomasDOI 10.1101/2022.03.10.482967Read

Expanding Microgel Parameters to Model the Tumor Microenvironment and Examine Temozolomide Resistance in GlioblastomaSemantic proximity Read

Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicineSemantic proximity Read

Modular mechanistic mathematical models for improved biomarker identification and treatment scheduling in oncologySemantic proximity Read

Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.Semantic proximity Read

Towards more accurate preclinical glioblastoma modelling: reverse translation of clinical standard of care in a glioblastoma mouse modelSemantic proximity Read

Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibitionSemantic proximity Read

Mathematical modeling identifies optimum lapatinib dosing schedules for the treatment of glioblastoma patients.Semantic proximity Read

Personalized Glioblastoma Multiforme Growth Modeling by Integrating Clinical Genomic and Phenotypic DataSemantic proximity Read

From cells to tissue: How cell scale heterogeneity impacts glioblastoma growth and treatment response.Semantic proximity Read

Quantifying the Role of Angiogenesis in Malignant Progression of Gliomas: <i>In Silico</i> Modeling Integrates Imaging and HistologySemantic proximity Read

Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair InhibitionSemantic proximity Read

Feasibility of an Evolutionary Tumor Board for Generating Novel Personalized Therapeutic StrategiesSemantic proximity Read